SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-012895
Filing Date
2023-08-02
Accepted
2023-08-02 16:01:10
Documents
14
Period of Report
2023-08-02
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20230802x8k.htm   iXBRL 8-K 37330
2 EX-3.1 kala-20230802xex3d1.htm EX-3.1 8530
3 EX-3.2 kala-20230802xex3d2.htm EX-3.2 173558
  Complete submission text file 0001558370-23-012895.txt   367627

Data Files

Seq Description Document Type Size
4 EX-101.SCH kala-20230802.xsd EX-101.SCH 3124
5 EX-101.LAB kala-20230802_lab.xml EX-101.LAB 15917
6 EX-101.PRE kala-20230802_pre.xml EX-101.PRE 10117
8 EXTRACTED XBRL INSTANCE DOCUMENT kala-20230802x8k_htm.xml XML 4814
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 231135390
SIC: 2834 Pharmaceutical Preparations